Avantax Advisory Services Inc. Boosts Stock Position in Laboratory Co. of America Holdings (NYSE:LH)

Avantax Advisory Services Inc. raised its stake in shares of Laboratory Co. of America Holdings (NYSE:LHFree Report) by 7.2% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,651 shares of the medical research company’s stock after buying an additional 111 shares during the quarter. Avantax Advisory Services Inc.’s holdings in Laboratory Co. of America were worth $332,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in LH. Eagle Bay Advisors LLC purchased a new position in shares of Laboratory Co. of America during the 2nd quarter worth $29,000. Tradewinds Capital Management LLC purchased a new position in shares of Laboratory Co. of America during the 3rd quarter worth $34,000. Exchange Traded Concepts LLC purchased a new position in shares of Laboratory Co. of America during the 3rd quarter worth $37,000. ST Germain D J Co. Inc. purchased a new position in shares of Laboratory Co. of America in the 2nd quarter worth $43,000. Finally, UMB Bank n.a. raised its position in shares of Laboratory Co. of America by 22.1% in the 3rd quarter. UMB Bank n.a. now owns 315 shares of the medical research company’s stock worth $63,000 after buying an additional 57 shares during the period. Hedge funds and other institutional investors own 89.37% of the company’s stock.

Wall Street Analyst Weigh In

LH has been the topic of several research reports. Mizuho cut their target price on Laboratory Co. of America from $257.00 to $230.00 and set a “buy” rating on the stock in a research report on Tuesday, October 31st. JPMorgan Chase & Co. raised their price objective on Laboratory Co. of America from $259.00 to $261.00 and gave the company an “overweight” rating in a research report on Friday, November 17th. TheStreet raised Laboratory Co. of America from a “c+” rating to a “b-” rating in a research report on Thursday, January 18th. Evercore ISI initiated coverage on Laboratory Co. of America in a research note on Friday. They issued an “in-line” rating and a $240.00 price target for the company. Finally, Barclays assumed coverage on Laboratory Co. of America in a research note on Wednesday, January 3rd. They issued an “equal weight” rating and a $222.00 price target for the company. Five analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $241.86.

View Our Latest Research Report on Laboratory Co. of America

Laboratory Co. of America Price Performance

Shares of NYSE:LH opened at $227.50 on Tuesday. Laboratory Co. of America Holdings has a 12 month low of $174.20 and a 12 month high of $234.09. The stock has a market cap of $19.31 billion, a price-to-earnings ratio of 30.41 and a beta of 1.04. The stock’s 50 day moving average price is $223.60 and its 200 day moving average price is $213.28. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.36 and a quick ratio of 1.20.

Laboratory Co. of America Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 13th. Shareholders of record on Tuesday, February 27th will be given a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a yield of 1.27%. The ex-dividend date of this dividend is Monday, February 26th. Laboratory Co. of America’s payout ratio is 38.50%.

Insiders Place Their Bets

In other Laboratory Co. of America news, EVP Der Vaart Sandra D. Van sold 259 shares of Laboratory Co. of America stock in a transaction that occurred on Thursday, February 8th. The shares were sold at an average price of $222.06, for a total transaction of $57,513.54. Following the transaction, the executive vice president now directly owns 7,637 shares in the company, valued at approximately $1,695,872.22. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In related news, CAO Peter J. Wilkinson sold 1,384 shares of Laboratory Co. of America stock in a transaction on Thursday, November 16th. The shares were sold at an average price of $210.71, for a total value of $291,622.64. Following the completion of the sale, the chief accounting officer now owns 2,087 shares of the company’s stock, valued at approximately $439,751.77. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Der Vaart Sandra D. Van sold 259 shares of the business’s stock in a transaction on Thursday, February 8th. The stock was sold at an average price of $222.06, for a total transaction of $57,513.54. Following the transaction, the executive vice president now directly owns 7,637 shares of the company’s stock, valued at approximately $1,695,872.22. The disclosure for this sale can be found here. Corporate insiders own 0.65% of the company’s stock.

Laboratory Co. of America Company Profile

(Free Report)

Laboratory Corporation of America Holdings operates as a life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Labcorp Diagnostics and Labcorp Drug Development.

Featured Stories

Want to see what other hedge funds are holding LH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Laboratory Co. of America Holdings (NYSE:LHFree Report).

Institutional Ownership by Quarter for Laboratory Co. of America (NYSE:LH)

Receive News & Ratings for Laboratory Co. of America Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Co. of America and related companies with MarketBeat.com's FREE daily email newsletter.